Galapagos NV(GLPG) Stock Research - Grey Stern Research
Loading...

Galapagos NV (GLPG) Stock Analysis

$28.30 (-0.25%)

GLPG Financial Performance


Use the table below to view Galapagos NV's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $28.37 -
52 Week Low $24.16 -
52 Week High $42.46 -
Market Cap $1.9 Billion 1/8
Gross Margin 79% 4/8
Profit Margin 12% 1/8
EBITDA margin -53% 2/8
Q2 - 2024 Revenue $85.6 Million 1/8
Q2 - 2024 Earnings $9.9 Million 1/8
Q2 - 2024 Free Cash Flow -$140.0 Million 8/8
Trailing 4 Quarters Revenue $56.3 Million 3/8
Trailing 4 Quarters Earnings $310.5 Million 1/8
Quarterly Earnings Growth 76% 1/8
Annual Earnings Growth 278% 2/8
Quarterly Revenue Growth -48% 8/8
Annual Revenue Growth -93% 8/8
Cash On Hand $57.5 Million 3/8
Short Term Debt $4.5 Million 3/8
Long Term Debt $7.4 Million 3/8

Galapagos NV Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Galapagos NV's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 6.02 2/8
PS 30.23 2/8
PB 0.58 5/8
PC 32.51 2/8
Liabilities to Equity 0.47 5/8
ROA 0.07 2/8
ROE 0.11 2/8
Current Ratio 3.11 3/8
Quick Ratio 2.49 3/8
Long Term Debt to Equity 0.00 6/8
Debt to Equity 0.00 7/8
Burn Rate -6.10 8/8
Cash to Cap 0.03 7/8
CCR -14.18 8/8
EV to EBITDA -48.97 8/8
EV to Revenue 35.77 2/8

Company Details

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

CEO: Mr. Onno van de Stolpe

Website: https://www.glpg.com

Address: Generaal De Wittelaan L11 A3 Mechelen,

Exchange: NASDAQ Global Select

Industry: Biotechnology

Galapagos NV Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Galapagos NV. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
CytomX Therapeutics, Inc. CTMX $89.8 Million
Assembly Biosciences, Inc. ASMB $93.0 Million
Spero Therapeutics, Inc. SPRO $70.8 Million
Instil Bio, Inc. TIL $377.2 Million
NextCure, Inc. NXTC $37.2 Million
Nuvation Bio Inc. NUVB $737.7 Million
Achilles Therapeutics plc ACHL $40.7 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
GLPG Income Statements
Quarter Year Revenue Earnings
Q2 2024 € 77.9 Million €9.0 Million
Q1 2024 € 62.4 Million €90.2 Million
Q4 2023 € 209.1 Million €157.6 Million
Q3 2023 € 120.0 Million €25.8 Million
Q2 2023 € 150.0 Million €5.1 Million
Q1 2023 € 178.9 Million €23.2 Million
Q4 2022 € 95.1 Million -€207.2 Million
Q3 2022 € 136.2 Million €21.6 Million

View All

GLPG Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 €52.3 Million €4.3 Billion €10.9 Million €2.9 Billion
Q1 2024 €73.4 Million €4.4 Billion €8.0 Million €2.9 Billion
Q4 2023 €166.8 Million €4.4 Billion €9.6 Million €2.8 Billion
Q3 2023 €159.4 Million €4.5 Billion €14.1 Million €2.6 Billion
Q2 2023 €98.0 Million €4.5 Billion €15.4 Million €2.6 Billion
Q1 2023 $124.1 Million $4.6 Billion $16.0 Million $2.6 Billion
Q4 2022 €508.1 Million €4.7 Billion €21.9 Million €2.5 Billion
Q3 2022 €675.5 Million €5.0 Billion €22.7 Million €2.7 Billion

View All

GLPG Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 -€127.4 Million -€65.8 Million -€21.0 Million
Q1 2024 -€124.0 Million -€6.3 Million -€86.0 Million
Q4 2023 -€74.8 Million -€8.0 Million €7.4 Million
Q3 2023 -€122.0 Million -€3.2 Million €61.4 Million
Q2 2023 -€129.2 Million -€3.8 Million -€26.1 Million
Q1 2023 -€99.2 Million -€4.3 Million -€384.0 Million
Q4 2022 -€187.7 Million -€7.8 Million -€167.4 Million
Q3 2022 -€128.7 Million -€11.8 Million -€297.3 Million

View All